Medy-Tox Inc. (KOSDAQ:086900)

South Korea flag South Korea · Delayed Price · Currency is KRW
164,700
-8,000 (-4.63%)
Jun 5, 2025, 3:30 PM KST
19.18%
Market Cap 1.16T
Revenue (ttm) 237.99B
Net Income (ttm) 21.25B
Shares Out 7.02M
EPS (ttm) 2,677.00
PE Ratio 61.52
Forward PE 27.15
Dividend 1,100.00 (0.67%)
Ex-Dividend Date Sep 27, 2024
Volume 108,011
Average Volume 70,728
Open 172,700
Previous Close 172,700
Day's Range 163,300 - 172,800
52-Week Range 112,100 - 218,000
Beta 0.49
RSI 47.92
Earnings Date May 15, 2025

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 724
Stock Exchange KOSDAQ
Ticker Symbol 086900
Full Company Profile

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.

Financial Statements

News

There is no news available yet.